CryptoVision

SANOFI NOVAVAX NUVAXOVID BEATS MODERNA mrNA vaccine! THIS IS OFFICIAL! NOVAVAX NOW IS THE BEST COVID VACCINE ON EARTH! PROVEN! marketscreener.com/news/sano…

FUCK OFF CRYPTO! I AM DONE! THIS IS A FREAKIN SCAM INDUSTRY!!!!!!!!!!!! GTFO! EVEN HARD WARE WALLETS AREN'T SAFE ANYMORE! FCK $BTC $ETH BINANCE HACK WTF

People are going to figure out fairly soon that right now it's smarter to rotate out of Intel, SanDisk, Amazon, Reddit, Roblox and whatever else they're all called, and into biotech. First, because we're in cold and flu season — virus season. And second, because a company like Novavax has no large investments at all. No CapEx. What it has is royalty income from licensing agreements. And that business model, right now, I think is really worth gold. It's simply worth gold. I'm curious when the market finally wakes up. But in my opinion it can't take too much longer. At the latest when we see more good news next week. Hopefully from Novavax. NFA. Long $NVAX.

People are going to figure out fairly soon that right now it’s smarter to rotate out of $INTC, $SNDK, $AMZN, $RDDT, $RBLX and whatever else they’re all called, and into biotech. First, because we’re in cold and flu season — virus season. And second, because a company like $NVAX has no large investments at all. No CapEx. What it has is royalty income from licensing agreements. And that business model, right now, I think is really worth gold. It’s simply worth gold. I’m curious when the market finally wakes up. But in my opinion it can’t take too much longer. At the latest when we see more good news next week. Hopefully from Novavax.

🇨🇦 $NVAX Sanofi just turned Canada on. 🔛 Nuvaxovid is now in ALL 10 PROVINCES + Yukon for the 2026-27 season. Provincial respiratory programs. Most private insurers. 🏥 Live right now in BC, Alberta, Quebec. Ontario started the week of Oct 26. Pharmacies next. “Provincial programs” = publicly funded. 💵 That’s not a product begging for scripts. That’s a product written into government immunization programs. And read the number Sanofi themselves put in the release 👇 Canada, 2024-25 season: 🦠 120,000+ cases 🏥 33,500 hospitalizations ⚰️ 2,300 deaths 🚫 ~77% of adults didn’t get vaccinated at all Seventy. Seven. Percent. 😳 Sanofi isn’t fighting Moderna for market share here. They’re going after the people who won’t touch mRNA and currently take nothing. That’s the real TAM. 🎯 And notice who’s doing the work. Sanofi’s country GM. Sanofi’s press release. Sanofi’s advocacy partnerships. Sanofi’s provincial negotiations. 🤝 $NVAX paid for none of it. 🧊 That’s the whole model. Somebody else builds the machine. Novavax owns the molecule. 🧬 TIMING ⏰ — all of this lands in Q4. Q3 was the warm-up. €30M, the first number Sanofi has EVER printed for Nuvaxovid. Last year the line said $0. 📈 Now stack Q4: full season 🇬🇧🇩🇪🇨🇦🇺🇸🇯🇵 + the $125M milestone (footnote 2: November) + Takeda’s annual Japan milestone. Market cap $1.71B. That one milestone is 7.3% of the company. 🤯 Honest bit, because I don’t do one-sided: no dose numbers here, and being listed isn’t the same as being injected. Canada is 40M people — it won’t move Sanofi’s P&L. It moves the stack. 🧱 Thursday. Nov 5. Before the open. The royalty line prints. ⏰ (And that ~90% efficacy Sanofi quotes? That’s from the original pivotal Phase 3s, 2021 variants. I’ll quote it accurately or not at all. 🤓) I like the stock. 🚀 marketwirenews.com/stock/sny…

NEWSFLASH AT NOVAVAX! $NVAX CANADA SANOFI! Sanofi expands Canadians' COVID-19 vaccine choice with availability of Nuvaxovid®for the 2026-2027 respiratory season MWN-AI** Summary Sanofi Canada has announced the availability of Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, for the 2026-2027 respiratory season across all 10 provinces and the Yukon. This decision enriches the options available for Canadians seeking protection against COVID-19, as Nuvaxovid supplements existing mRNA vaccine offerings. The vaccine, showing around 90% efficacy in preventing symptomatic COVID-19 from clinical trials, is positioned to play a crucial role as respiratory viruses become more prevalent in colder months. Nuvaxovid is already accessible in British Columbia, Alberta, and Quebec, with plans for its rollout in Ontario starting October 26, 2026, through healthcare provider offices and public health units, expanding to pharmacies later. This initiative reflects Sanofi's commitment to public health and enhanced vaccine accessibility. marketwirenews.com/stock/sny…

🚨 $NVAX 🚨 Sanofi just put a NUMBER on Nuvaxovid. For the first time. Ever. 📊 €30 MILLION. Q3. Printed on their own slide. 🧾 Now go look at last year. Sanofi’s Q3 2025 deck: “First Nuvaxovid sales by Sanofi.” No euros. Not in the top-20 table. 🤷 Novavax’s own Q3 2025 report: “Nuvaxovid Sales: $0.” 🫥 ZERO ➡️ €30,000,000 📈 From “not worth quantifying” to a named line in the growth table. In twelve months. And I’ll say the quiet part before some bear does: ignore anyone selling you “650% QoQ.” Q2 is the OFF-season. That’s the calendar, not traction. I don’t need fake math — the real stuff is better. 🚫🧮 Because here’s what actually just changed 👇 THE ROYALTY RATE IS NOW CALCULABLE. 🔓 Every Sanofi document for two years says the same three words: “tiered royalties.” No percentage. Nobody could model this company. Not Citi. Not BofA. Nobody. 🙈 Thursday, Novavax reports Q3. Take the Sanofi royalty line. Divide by €30M. That’s the rate. First time in history it’s derivable. 🗝️ And Q3? Q3 is just the warm-up. July–September is the START of the season. Sanofi literally blamed the vaccine division on “anticipated phasing in respiratory prevention” — shipments pushed out. The volume is in Q4. ❄️🔥 LOOK AT WHAT’S STACKING INTO Q4 👇 💰 $125M milestone — footnote 2 says achievement in November 💰 Full respiratory season under Sanofi 💰 Takeda’s annual Japan milestone — XFG approved August, paid every single season 💰 Then $75M tech transfer. Then $225M on US launch. Then up to $500M from $PFE. Market cap: $1.71 BILLION. 💵 That $125M alone = 7.3% of the ENTIRE COMPANY. In cash. With zero cost against it. Oh and — ~33% of the float is short. 🩳🔥 Honest flip side, because one-sided pitches are worthless: €30M is 0.94% of Sanofi’s quarterly vaccine sales. Still a small product inside a giant partner. The way out is the combination — and they just dosed patient number five. 🧬 Thursday. Nov 5. Before the open. 8:30am ET. ⏰ One line on one page changes this entire thesis. I like the stock. 🚀 NFA. Long $NVAX.

novavax $NVAX

🚨 $NVAX 🚨 Big Tech is about to spend $700,000,000,000 this year. Seven hundred BILLION. 💸 $AMZN ~$200B. $MSFT ~$190B. $GOOG $180–190B. $META $125–145B. Up 75% in ONE year. Eating nearly ALL their operating cash flow. Some of it now on DEBT. 🏦 And the shovel sellers are eating like kings 👑 $CAT reported TODAY: record $20.7B quarter, +17%. Profit $3.3B, +43%. Backlog $78 BILLION — nearly DOUBLE last year. Power gen +30%, straight out of data centers. $NOW and $FTNT feeding at the same trough. Somebody has to pay for all that concrete and silicon. 🧱⚡ Meanwhile. Today. Quietly. 🤫 $NVAX booked $125,000,000. 💰 CAPEX REQUIRED: ZERO. 🎯 ❌ No data center ❌ No fab ❌ No factory ❌ No Phase 3 budget ❌ No sales force ❌ No inventory ❌ No backlog to deliver ❌ No depreciation schedule anyone has to guess at Sanofi runs the trial. Sanofi PAYS for the trial. Sanofi dosed patient number five in Europe. Novavax got the wire. 📩 One patient. One shot. $125 MILLION. 🤯 ≈ $0.76 per share. Cost-free. 165M shares. My math — go check it. 🧮 AND THE LADDER IS STILL LOADED 🪜 💵 $75M — tech transfer 💵 $225M — US launch of the flu-COVID combo 💵 up to $500M — $PFE, for Matrix-M 💵 Royalties. On all of it. Forever. Oh — and 32.38% of the float is short. 47,348,523 shares. 7.17 days to cover. 🩳🔥 A THIRD of the float betting against a company that gets PAID for work somebody else performs. Honest flip side, because I don’t do one-sided: capital-light means Sanofi keeps the margin. Lower ceiling. Also WAY lower risk. 🤝 Wall Street is screaming about whether a six-year GPU useful life is real. 🖥️⏳ Nobody has to guess what a milestone payment depreciates to. 📈 Q3 Thursday. Nov 5. 8:30am ET. ⏰ I like the stock. 🚀

🚨 WALL STREET IS WATCHING THE WRONG ROCKET. 🚨 Everyone’s talking about the AI trade. $GOOGL $NOW $FTNT $TSLA $MSFT 📉 Meanwhile, something BIG just happened in BIOTECH. 🧬 $NVAX JUST HIT A $125 MILLION SANOFI MILESTONE! 💰🔥 Not AI promises. Not another hype-fueled valuation. A REAL $125 MILLION MILESTONE. And the market is STILL sleeping?! 👀 They chased the hype. We held the science. They panic. We accumulate. 💎🙌 THE SLEEPING GIANT IS WAKING UP. 🦍 And when Wall Street finally notices… 🚀🚀🚀 NOVAVAX FAM. DIAMOND HANDS. STEEL NERVES. $NVAX #Novavax #Biotech #DiamondHands

125mio!!!!! For one patient getting one shot in Europe. Patient number five. That's it. That was the trigger. Sanofi runs the Phase 3. Sanofi pays for the Phase 3. $NVAX gets the wire. No factory. No sales force. No inventory. No risk. ~$0.76 per share. Pure. One event. And the ladder isn't done: $75M on tech transfer. $225M on US launch. Royalties on top of royalties. Oh and — 32.38% of the float is short. 47.3 million shares. 7.17 days to cover. Betting against a company that gets paid for work other people do. Q3 Thursday, 8:30am ET. I like the stock.

NOVAVAX IS BETTER THAN MRNA. NOTHING TO ADD! POINT. $NVAX

novavax $NVAX ir.novavax.com/press-release…

SWEDEN COVID VACCINE NOVAVAX $NVAX WE LOVE SWEDEN!!!

$NVAX NOVAVAX LET'S GO!!!

MONOPOL NOVAVAX $NVAX NUVAXOVID COVID PROTEIN BASED VACCINE FOR SWEDEN. mRNA IN SWEDEN IS OVER!!! WELL DONE, SWEDEN!

breaking! cantor fitzgerald anyalst "overweight" price target $18! NOVAVAX $NVAX